European Increlex® (Mecasermin [rDNA Origin] Injection) Growth Forum Database - IGFD Registry (EuIGFD)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT00903110
Recruitment Status : Recruiting
First Posted : May 15, 2009
Last Update Posted : April 30, 2018
Information provided by (Responsible Party):

Brief Summary:
The Eu-IGFD is a descriptive, multicenter, observational, prospective, open-ended, non interventional, post-authorisation surveillance registry. The purpose of this study is to collect long-term safety information on the use of recombinant DNA-derived human Insulin-like Growth Factor-1 (rhIGF-I) Increlex® replacement therapy for the treatment of children with growth failure.

Condition or disease Intervention/treatment
IGF1 Deficiency Drug: Increlex®

Detailed Description:

Surveillance registry, defined as a post-authorisation observational registry, called the Eu-IGFD {European Increlex® (Mecasermin [rDNA Origin] Injection) Growth Forum Database} which is intended primarily to monitor the safety of Increlex® replacement therapy in children with growth failure and secondly to follow the effectiveness of this treatment. Patients who have already started Increlex® therapy before entering this observational registry may be included in this registry and data will be collected retrospectively.

The countries participating in this registry are Austria, Belgium, France, Germany, Italy, The Netherlands, Poland, Spain, Sweden, and United Kingdom.

Study Type : Observational
Estimated Enrollment : 330 participants
Observational Model: Case-Only
Time Perspective: Other
Official Title: European Increlex® (Mecasermin [rDNA Origin] Injection) Growth Forum Database: a European Registry for Monitoring Long Term Safety and Efficacy of Increlex®. Eu-IGFD
Study Start Date : December 2008
Estimated Primary Completion Date : December 2023
Estimated Study Completion Date : December 2023

Resource links provided by the National Library of Medicine

Drug Information available for: Mecasermin

Intervention Details:
  • Drug: Increlex®
    Increlex® (mecasermin [rDNA origin] injection), 10 mg/ml solution for injection, 20-120mcg/kg BID or 0,02 to 0,12 mg/kg BID, as prescribed by physician

Primary Outcome Measures :
  1. Serious adverse events including any occurrence of neoplasia [ Time Frame: throughout study ]

Secondary Outcome Measures :
  1. All other non-serious adverse events considered to be drug-related by the paediatric endocrinologist [ Time Frame: follow up to post-treatment visits ]
  2. All targeted adverse events [ Time Frame: follow up to post treatment visits ]
  3. All clinically significant laboratory abnormalities [ Time Frame: throughout study ]
  4. Dose of Increlex® at the start of the treatment, dose escalation, concomitant medication, height, weight, pubertal age, predicted Adult Height, height velocity, final adult height, pubertal stage [ Time Frame: periodically assessed during the study until the final adult height is achieved ]
  5. Biological assessment : IGF-1 levels, IGFBP-3 levels, baseline GH concentrations and binding proteins. [ Time Frame: throughout study ]
  6. Genetic test results if available [ Time Frame: throughout study ]

Biospecimen Retention:   None Retained
Study Design Time Perspective: Retrospective and Prospective

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   2 Years to 17 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Children with Growth Failure due to Severe Primary IGF-1 Deficiency

Inclusion Criteria:

  • All subjects beginning therapy with Increlex® or those previously treated with Increlex® by a participating qualified practitioner
  • Parents or legally authorized representatives if applicable must give signed informed consent before any registry-related activities are conducted. Assent from the subject should also be obtained as appropriate

Exclusion Criteria:

  • Subject currently participating in an Increlex® clinical trial
  • Subject currently participating in any clinical trial for growth retardation

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00903110

Contact: Ipsen Recruitment Enquiries

United Kingdom
Ipsen Central Contact Recruiting
Slough, Berkshire, United Kingdom
Sponsors and Collaborators
Study Director: Caroline Sert, MD Ipsen

Responsible Party: Ipsen Identifier: NCT00903110     History of Changes
Other Study ID Numbers: 2-79-52800-002
EUPAS7708 ( Other Identifier: EU PAS Register )
First Posted: May 15, 2009    Key Record Dates
Last Update Posted: April 30, 2018
Last Verified: April 2018

Additional relevant MeSH terms:
Growth Substances
Physiological Effects of Drugs